8 "Pancreas" clinical trials found.
-
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
If you have been diagnosed with a rare cancer or a rare cancer of unknown primary origin, you may qualify for this study. The main ...
-
Precision Promise Platform Trial for Metastatic Pancreatic Cancer Precision PromiseSM
The purpose of this study is to hope that Precision PromiseSM will change the landscape of clinical development in pancreatic cancer and open the door ...
-
A Phase 1-2 First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Lymphomas.
The study is being done to look at: • The possible side effects, safety and tolerability of CX-2029 • The highest dose of CX-2029 that ...
-
A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
The purpose of the study to determine the safety of CYT-0851 in patients with relapsed/refractory B-Cell malignancies and advanced solid tumors. The study drug CYT-0851 ...
-
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)
The purpose of the study is to look at safety and efficacy of study drug ABBV-151 alone and in combination with study drug ABBV-181. We ...
-
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
The purpose of this study is to understand whether potential new drugs, AB680 and AB122, can be safely given to patients with pancreatic cancer in ...
-
A Phase 1 Open Label Multi-Arm Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors
This is a first-in-human (FIH), dose escalation, and dose finding trial to assess the safety and tolerability of MK-4830, both as monotherapy and as combination ...
-
An Open Label First in Human (FIH) Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda (pembrolizumab) in Advanced or Metastatic Malignancy
The purpose of the study is to look at how your body tolerates LVGN6051, how safe LVGN6051 may be, and how LVGN6051 is taken up ...
